IHCP bulletin

INDIANA HEALTH COVERAGE PROGRAMS

BT2025134 SEPTEMBER 30, 2025

Pharmacy updates approved by Drug Utilization Review Board September 2025

The Indiana Health Coverage Programs (IHCP) announces updates to the Point of Sale Quick Check (PSQC) automated prior authorization (PA) system, PA criteria, Statewide Uniform Preferred Drug List (SUPDL) and Preferred Brand Drug List as approved by the Drug Utilization Review (DUR) Board at its Sept. 19, 2025, meeting.

PSQC PA enhancement

The IHCP has enhanced its automated PA system to update the criteria for Multiple Sclerosis PA. These PA changes will be effective for PA requests submitted on or after Dec. 1, 2025. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* webpage on the Optum Rx Indiana Medicaid website, accessible from the *Pharmacy Services* webpage at in.gov/medicaid/providers.



PA changes

PA criteria for Amyloid-Beta-Directed Antibodies, Complement Inhibitor Agents, Cushing's Syndrome Agents, GLP-1 RA/GIP RA/Combination Agents PA with QL, Non-SUPDL Agents PA and Step Therapy, Phenylketonuria Agents, and Thrombopoietin Receptor Agonist Agents were established and approved by the DUR Board. PA criteria for Amyloid-Beta-Directed Antibodies, Complement Inhibitor Agents, Cushing's Syndrome Agents, Non-SUPDL Agents PA and Step Therapy, Phenylketonuria Agents, and Thrombopoietin Receptor Agonist Agents apply to the fee-for-service (FFS) benefit only. These PA changes will be effective for PA requests submitted on or after Dec.1, 2025. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* webpage on the <u>OptumRx Indiana Medicaid website</u>.

Changes to the SUPDL

Changes to the SUPDL were made at the Sept. 19, 2025, DUR Board meeting. See Table 1 for a summary of SUPDL changes, effective for FFS and managed care claims with dates of service (DOS) on or after Dec. 1, 2025.

Table 1 – SUPDL changes, effective for FFS and managed care claims with DOS on or after Dec. 1, 2025

Drug class	Drug	SUPDL status
Multiple Sclerosis	Ampyra (dalfampridine) – brand only	Nonpreferred (previously preferred)
Pulmonary Antihypertensives	bosentan dispersible tablet – generic only	Nonpreferred (previously preferred)

Changes to the Preferred Brand Drug List

Changes to the Preferred Brand Drug List were made at the Sept. 19, 2025, DUR Board meeting. See Table 2 for a summary of Preferred Brand Drug List changes, effective for FFS and managed care claims with DOS on or after Dec.1, 2025.

Table 2 – Updates to Preferred Brand Drug List, effective for FFS and managed care claims with DOS on or after Dec. 1, 2025

Name of medication	Preferred Brand Drug List status
Adzenys XR (amphetamine) ODT tablet	Add to Preferred Brand Drug List
Tracleer (bosentan) dispersible tablet	Add to Preferred Brand Drug List
Venofer (iron sucrose)	Add to Preferred Brand Drug List
Cloderm (clocortolone) cream	Remove from Preferred Brand Drug List
Motegrity (prucalopride) tablet	Remove from Preferred Brand Drug List

For more information

The PSQC criteria, PA criteria, SUPDL and Preferred Brand Drug List can be found on the Optum Rx Indiana Medicaid website. Notices of the DUR Board meetings and agendas are posted on the Indiana Family and Social Services Administration (FSSA) website at in.gov/fssa. Click FSSA Calendar on the left side of the page to access the events calendar.

Please direct FFS pharmacy PA requests and questions about the SUPDL under the FFS pharmacy benefit or about this bulletin to the Optum Rx Clinical and Technical Help Desk by calling toll-free 855-577-6317.

Individual managed care entities (MCEs) establish and publish PA criteria within the managed care delivery system. Questions about managed care PA should be directed to the MCE with which the member is enrolled.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the IHCP Bulletins page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the IHCP provider website at in.gov/medicaid/providers.

